PAION IS HOSTING A SPONSORED ANGIOTENSIN II SYMPOSIUM AT ISICEM IN BRUSSELS

EQS-Information: PAION AG

/ Key phrase(s): Convention

PAION IS HOSTING A SPONSORED ANGIOTENSIN II SYMPOSIUM AT ISICEM IN BRUSSELS
16.03.2023 / 10:00 CET/CEST
The issuer is solely accountable for the content material of this announcement.

PAION IS HOSTING A SPONSORED ANGIOTENSIN II SYMPOSIUM AT ISICEM IN BRUSSELS

Sponsored Symposium & poster presentation about angiotensin II at forty second ISICEM 2023, 21-24 March 2023, Brussels
PAION to current new knowledge from a publish hoc evaluation of the ATHOS-3 research with angiotensin II

Aachen (Germany), 16 March 2023 – PAION AG (ISIN DE000A0B65S3; Frankfurt Inventory Trade, Prime Customary: PA8), a specialty pharmaceutical firm with revolutionary compounds to be used in outpatient and in-hospital sedation, anesthesia and intensive care, will take part on the ISICEM 2023, Worldwide Symposium on Intensive Care and Emergency Medication, 21-24 March 2023, Brussels. One summary about angiotensin II has been accepted for a presentation. As well as, PAION has organised a Sponsored Symposium.

Poster presentation:

Angiotensin II for the remedy of vasodilatory shock in sufferers with acute kidney harm. Poster quantity P219

This publish hoc evaluation helps to know which group of sufferers may be additional studied to find out advantages from remedy with angiotensin II.

Sponsored Symposium:

Administration of refractory distributive shock: new insights and sensible features

Wednesday 22 March 2023, 12.30–13.30 (CET).

Angiotensin II is authorized by the European Fee for the remedy of refractory hypotension in adults with septic or different distributive shock who stay hypotensive regardless of ample quantity restitution and utility of catecholamines and different obtainable vasopressor therapies.

PAION estimates about 150,000 septic or different distributive shock sufferers in Europe yearly remaining under goal blood strain ranges regardless of remedy with present therapies resulting in a excessive mortality fee in these critically sick sufferers.

Gregor Siebert, CEO of PAION AG, commented: “Septic and different distributive shock is a severe situation that ends in elevated mortality in hospitalized sufferers. Thus, this requires a fancy remedy by intensive care specialists, the place PAION comes into play. With our product angiotensin II, we’re making a precious contribution to the remedy of adults right here. We’re excited to additional intensify the dialogue with intensive care specialists and key opinion leaders and proceed to studying what is required in observe. The symposium at ISICEM gives a really perfect platform for this.”

Angiotensin II (GIAPREZA^®) at a look

Angiotensin II for injection is an FDA-approved vasoconstrictor to extend blood strain in adults with septic or different distributive shock. Angiotensin II is authorized by the European Fee for the remedy of refractory hypotension in adults with septic or different distributive shock who stay hypotensive regardless of ample quantity restitution and utility of catecholamines and different obtainable vasopressor therapies. Angiotensin II mimics the physique’s endogenous angiotensin II peptide, which is central to the renin-angiotensin-aldosterone system, which in flip regulates blood strain.

Angiotensin II raises blood strain by vasoconstriction; elevated aldosterone launch by way of direct motion of angiotensin II on the vessel wall is mediated by binding to the G-protein-coupled angiotensin II receptor kind 1 on vascular easy muscle cells which stimulates Ca2+/calmodulin dependent phosphorylation of myosin and causes easy muscle contraction.

The pivotal part III trial of angiotensin II for the remedy of high-output shock (ATHOS-3) was a randomized, placebo-controlled, double-blind, worldwide, multicenter Part III security and efficacy trial by which adults with septic shock or different distributive shock who had hypotension regardless of fluid and vasopressor remedy had been randomized 1:1 to angiotensin II or placebo, and 321 sufferers had been handled. The first efficacy endpoint, a rise in blood strain, was achieved by 70 % of sufferers handled with angiotensin II in contrast with 23 % of sufferers handled with placebo; p < 0.001.

The European Abstract of Product Traits is out there on the European Medicines Company web site: www.ema.europa.eu/en/medicines/human/EPAR/giapreza

About PAION

PAION AG is a publicly listed specialty pharmaceutical firm with revolutionary medication for use in hospital-based sedation, anesthesia and significant care providers. PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic. PAION is rolling out remimazolam (Byfavo^®) in chosen European markets. Remimazolam is partnered in a number of territories exterior of Europe. Remimazolam is authorized within the U.S., the EU/EEA/UK, China and South Korea for procedural sedation and in Japan and South Korea for basic anesthesia.

As well as, PAION markets two intensive care merchandise in chosen European international locations: Angiotensin II (GIAPREZA^®), a vasoconstrictor indicated for the remedy of refractory hypotension in adults with septic or different distributive shock, and eravacycline (XERAVA^®), a novel fluorocycline kind of antibiotic indicated for the remedy of difficult intra-abdominal infections in adults.

PAION’s mission is to be a number one specialty pharmaceutical firm within the fields of anesthesia and significant care by bringing novel merchandise to market to learn sufferers, medical doctors and different stakeholders in healthcare.

PAION is headquartered in Aachen (Germany).

Contact

Ralf Penner

Senior Vice President Investor Relations & Company Communications

PAION AG

Heussstrasse 25

52078 Aachen – Germany

Cellphone +49 241 4453-152

E-mail r.penner@paion.com

www.paion.com

Disclaimer:

This launch incorporates sure forward-looking statements regarding the future enterprise of PAION AG. These forward-looking statements contained herein are primarily based on the present expectations, estimates and projections of PAION AG’s administration as of the date of this launch. They’re topic to a lot of assumptions and contain identified and unknown dangers, uncertainties and different elements. Ought to precise circumstances differ from PAION AG’s assumptions, precise outcomes and actions could differ materially from any future outcomes and developments expressed or implied by such forward-looking statements. Contemplating the dangers, uncertainties and different elements concerned, recipients mustn’t rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically replace any such forward-looking statements to mirror future occasions or developments.

16.03.2023 CET/CEST Dissemination of a Company Information, transmitted by EQS Information – a service of EQS Group AG.
The issuer is solely accountable for the content material of this announcement.

The EQS Distribution Companies embrace Regulatory Bulletins, Monetary/Company Information and Press Releases.
Archive at www.eqs-news.com